Jubilant Pharmova Limited has informed the Exchange about General Updates - USFDA Inspection Update - Contract manufacturing facility at Montreal, Canada
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova's subsidiary Jubilant HollisterStier General Partnership (JHSGP) has received a Warning Letter from the USFDA following an inspection at its Kirkland, Canada facility conducted from October 20 to November 3, 2025. The letter was received on May 28, 2026. JHSGP, which manufactures sterile products including liquid and lyophilized injectables, ophthalmic solutions and sterile ointments for global pharmaceutical clients, stated it has proactively engaged with the USFDA and initiated corrective and preventive actions. The company emphasized that current operations are proceeding under enhanced controls and oversight while remediation efforts are underway. JHSGP is jointly owned by subsidiaries of Jubilant Pharmova, Jubilant HollisterStier Inc., Draxis Pharma LLC and another entity.
A USFDA Warning Letter is a serious regulatory action that could potentially affect the company's ability to supply products to US clients. Depending on client reactions and the outcome of remediation efforts, this could create near-term uncertainty for the stock. However, the company's communication that operations are continuing under enhanced controls suggests no immediate disruption.